PROTOKOLwiki
COMPOUNDS / PEPTIDE / GHRP-6
PEPTIDE

GHRP-6

MEDIUM RISK
BEST FOR:Recovery●●●●●○○○○○5/10
GHRP-6 · GROWTH HORMONE RELEASING PEPTIDE-6 · GROWTH HORMONE RELEASING HEXAPEPTIDE · HIS-D-TRP-ALA-TRP-D-PHE-LYS-NH2
PeptideGH SecretagogueGhrelin AgonistRecoveryResearch ChemicalWADA Banned

Synthetic growth hormone secretagogue that stimulates GH release via ghrelin receptor agonism, used in performance and recovery contexts.

ROUTE / DOSAGE
LOW200mcg
STANDARD300-500mcg
HIGH800mcg
Note: Very low oral bioavailability (~3%); impractical route
CYCLE
1-3x daily 4-8 week cycles with 4-week break
BIOAVAILABILITY
~100% subq/im ~3% oral
ACTIVE DURATION
1-2h (subjective)
STORAGE
Lyophilized powder: -20°C frozen reconstituted: 2-8°C refrigerated use within 2-4 weeks protect from light
HALF-LIFE
~30 min (plasma)
DURATION BREAKDOWN
Total1-2h
Onset15-30 min
Come up15-30 min
Peak30-60 min
Offset30-60 min
After effects1-3h
Duration varies by route, dose, and individual. Source: community reports.
§ 01 — EFFECTS
6 documented
Increased growth hormone release
Increased appetite (ghrelin-mimetic)
Improved sleep quality
Enhanced recovery and tissue repair
Anti-inflammatory and cardioprotective effects
Transient cortisol and prolactin elevation
§ 02 — RISKS
Elevated cortisol and prolactin with repeated dosing
Potential insulin resistance with chronic use
Intense hunger stimulation may be undesirable
No long-term human safety data for performance use
Risk of contamination from unregulated research chemical sources
WADA-prohibited in competitive sport
§ 03 — INTERACTIONS
Interaction data not yet available for this compound.
§ 04 — SCIENCE

GHRP-6 has been studied since the late 1980s as a diagnostic tool for assessing pituitary GH reserve, showing reproducible GH stimulation across age groups and metabolic states. Animal studies demonstrate cardioprotective effects, including prevention of doxorubicin-induced cardiomyopathy via upregulation of prosurvival gene Bcl-2 and preservation of mitochondrial integrity. Recent work shows renoprotective potential in acute kidney injury through metabolic reprogramming of tubular epithelial cells. However, human clinical evidence beyond diagnostic use remains limited, and GHRP-6 is not approved for therapeutic use in any major jurisdiction. Most performance and longevity applications rely on extrapolation from animal data and anecdotal reporting.

§ 06 — SOURCES
[1]
GHRP-6 test in the diagnosis of GH-deficiency
pubmed.ncbi.nlm.nih.gov ↗
[2]
GHRP-6 hydrogel for acute kidney injury therapy via metabolic regulation
pubmed.ncbi.nlm.nih.gov ↗
[3]
GHRP-6 prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms
pubmed.ncbi.nlm.nih.gov ↗
[4]
[D-Lys3]-GHRP-6 exhibits pro-autophagic effects on skeletal muscle
pubmed.ncbi.nlm.nih.gov ↗
[5]
Evaluation of pituitary GH reserve with GHRP-6
pubmed.ncbi.nlm.nih.gov ↗
[6]
Detection of GHRP-2 and GHRP-6 in urine samples from athletes
pubmed.ncbi.nlm.nih.gov ↗
[7]
D-Lys-3-GHRP-6 impairs memory consolidation and downregulates hippocampal receptors
pubmed.ncbi.nlm.nih.gov ↗
Disclaimer. Protokol.wiki is an informational reference. Nothing on this site is medical advice. Compounds listed may be unapproved, unregulated, or illegal in your jurisdiction. Consult a licensed physician before use. Data compiled from peer-reviewed literature.
METHODOLOGYCONTRIBUTECONTACT